Ameliyatsız Primer Baş ve Boyun Malignitelerinde Radyoterapi Sonrası Tiroid Fonksiyonlarının Değerlendirilmesi

Abstract

Amaç: Bu çalışmada primer baş ve boyun malignitesi nedeniyle radyoterapi uygulanan hastalarda tiroid fonksiyon bozukluğunun araştırılması amaçlandı. Gereç ve Yöntemler: Çalışma 1 Ocak 2008 ile 31 Ocak 2017 tarihleri arasında Zonguldak Bülent Ecevit Üniversitesi Tıp Fakültesi Hastanesi'nde baş ve boyun bölgesinin primer malignitesi nedeniyle radyoterapi alan ve ameliyat geçirmeyen hastalarla gerçekleştirildi. Veriler retrospektif olarak hastane kayıtlarından kaydedildi. Bulgular: Toplam 132 kanser hastasının sonuçları incelendi. İncelenen bireylerin %52.28 (n = 69) glottik / supraglottik larinks kanseri, %15.15 (n = 20) nazofarenks kanseri ve %6.06 (n = 8) hodgkin lenfoma hastalarından oluşuyordu. Hastaların %78.8'i (n = 104) erkekti ve ortanca yaş 60.5 idi. Medyan tedavi süresi 44 (min = 8, maks = 354) gündü. Hastaların %28.8'inde (n = 38) anormal TSH değeri saptandı. Bireylerin %15.9'unda (n = 21) hipotiroidizm, %12.9'unda (n = 17) hipertiroidizm gelişti. Radyoterapi öncesi dönemde TSH anormalliği %29.0'ında (n = 11) ve radyoterapi sonrası dönemde %71.0'ında tespit edildi. Normal TSH grubu ile radyoterapi sonrası anormal TSH'si olanlar arasında yaş ve cinsiyet açısından anlamlı fark yoktu; ancak radyoterapi öncesi anormal TSH değeri olan hastaların yaşı anlamlı olarak daha yüksekti (p <0.001). Sonuç: Radyoterapi alan baş ve boyun malignitesi olan hastaların rutin takibinde, özellikle subklinik vakaların erken saptanması için tiroid fonksiyon testlerinin incelenmesi önemli olabilir.

Keywords

• Baş ve boyun maligniteleri
• radyoterapi
• tiroid disfonksiyonu

Evaluation of Thyroid Functions After Radiotherapy in Primary Head and Neck Malignancies without Surgery

Abstract

Aim: In this study, it was aimed to investigate thyroid dysfunction in patients who underwent radiotherapy due to primary head and neck malignancy. Material and Methods: The study was carried out between January 1, 2008 and January 31, 2017 at Zonguldak Bulent Ecevit University Health Practice and Research Hospital with patients who received radiotherapy due to primary malignancy of the head and neck region and did not undergo surgery. The data were recorded retrospectively from hospital records. All analyses were performed on SPSS v21 (SPSS Inc., Chicago, IL, USA). Two-tailed p-values of less than 0.05 were considered statistically significant. Results: The results of a total of 132 cancer patients were examined. Cancers examined mostly consisted of 52.28% (n = 69) glottic / supraglottic larynx cancer, 15.15% (n = 20) nasopharynx cancer, and 6.06% (n = 8) hodgkin lymphoma patients. In addition to ;78.8% (n = 104) of the patients were male and the median age was 60.5 (min = 15, max = 84) years. Median duration of treatment was 44 (min = 8, max = 354) days. It was determined that 28.8% (n = 38) of the patients had abnormal TSH value. Hypothyroidism developed in 15.9% (n = 21) of the individuals and hyperthyroidism developed in 12.9% (n = 17). And 29.0% (n = 11) of the TSH abnormalities determined in the preradiotherapy period and 71.0% in the post-radiotherapy period. There was no significant difference in age and gender between the normal TSH group and those that had abnormal TSH after radiotherapy; however, the age of patients with abnormal TSH value before radiotherapy was significantly higher (p <0.001). Conclusion: Thyroid dysfunction in head and neck malignancies may also be seen before treatment, but the frequency of thyroid dysfunction increases after radiotherapy. The effect of radiotherapy on the thyroid gland is not affected by variables such as age and gender. Patients who develop thyroid dysfunction after radiotherapy were younger than patients with thyroid dysfunction before radiotherapy. In the routine follow-up of patients with head and neck malignancy who receive radiotherapy, the examination of thyroid function tests could be important for the early detection of particularly subclinical cases.

Keywords

• Head and neck malignancies
• Radiotherapy
• Thyroid dysfunction

References

1. 1. Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, Ford I, Gussekloo J, Kearney PM, Mooijaart S, Quinn T, Stott D, Westendorp R, Rodondi N, Dekkers OM. Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis. JAMA.2018;320(13):1349-59. doi: 10.1001/jama.2018.13770
2. 2. Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid. 2002;12(10):839-47. doi: 10.1089/105072502761016458
3. 3. Boomsma MJ, Bijl HP, Langendijk JA. Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. Radiother Oncol. 2011;99(1):1-5. doi: 10.1016/j.radonc. 2011.03.002
4. 4. Lin CL, Wu SY, Huang WT, Feng YH, Yiu CY, Chiang WF, Ho SY, Lin SH. Subsequent thyroid disorders associated with treatment strategy in head and neck cancer patients: a nationwide cohort study. BMC Cancer. 2019;19(1):461. doi: 10.1186/ s12885-019-5697-y
5. 5. Feen Rønjom M. Radiation-induced hypothyroidism after treatment of head and neck cancer. Dan Med J. 2016;63(3):B5213
6. 6. Mulholland GB, Zhang H, Nguyen NT, Tkacyzk N, Seikaly H, O’Connell D, Biron VL, Harris JR. Optimal detection of hypothyroidism in early stage laryngeal cancer treated with radiotherapy. J Otolaryngol Head Neck Surg. 2015;44(1):34. doi: 10.1186/s40463-015-0085-3
7. 7. Fujiwara M, Kamikonya N, Odawara S, Suzuki H, Niwa Y, Takada Y, Doi H, Terada T, Uwa N, Sagawa K, Hirota S. The threshold of hypothyroidism after radiation therapy for head and neck cancer: a retrospective analysis of 116 cases. J Radiat Res. 2015;56(3):577-82. doi: 10.1093/jrr/rrv006
8. 8. Fan CY, Lin CS, Chao HL, Huang WY, Su YF, Lin KT, Tsai IJ, Kao CH. Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population- Based Cohort Study. Radiother Oncol. 2017;123(3):394- 400. doi: 10.1016/j.radonc.2017.04.025

9. 9. Kamal M, Peeler CR, Yepes P, Mohamed ASR, Blanchard P, Frank S, Chen L, Jethanandani A, Kuruvilla R, Greiner B, Harp J, Granberry R, Mehta V, Rock C, Hutcheson K, Cardenas C, Gunn GB, Fuller C, Mirkovic D. Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma. Adv Radiat Oncol. 2019;5(1):111-9. doi: 10.1016/j.adro.2019.08.006
10. 10. Chyan A, Chen J, Shugard E, Lambert L, Quivey JM, Yom SS. Dosimetric predictors of hypothyroidism in oropharyngeal cancer patients treated with intensity-modulated radiation therapy. Radiat Oncol. 2014;9:269. doi: 10.1186/s13014-014-0269-4
11. 11. Akgun Z, Atasoy BM, Ozen Z, Yavuz D, Gulluoglu B, Sengoz M, Abacioglu U. V30 as a predictor for radiation-induced hypothyroidism: a dosimetric analysis in patients who received radiotherapy to the neck. Radiat Oncol. 2014;9:104. doi: 10.1186/1748-717X-9-104
12. 12. Murthy V, Narang K, Ghosh-Laskar S, Gupta T, Budrukkar A, Agrawal JP. Hypothyroidism after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for head and neck cancers: prospective data from 2 randomized controlled trials. Head Neck. 2014;36(11):1573-80. doi: 10.1002/ hed.23482
13. 13. Koc M, Capoglu I. Thyroid dysfunction in patients treated with radiotherapy for neck. Am J Clin Oncol. 2009;32(2):150-3. doi: 10.1097/COC.0b013e3181845517
14. 14. Garcia-Serra A, Amdur RJ, Morris CG, Mazzaferri E, Mendenhall WM. Thyroid function should be monitored following radiotherapy to the low neck. Am J Clin Oncol. 2005;28(3):255-8. doi: 10.1097/01.coc.0000145985.64640.ac
15. 15. Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. Front Endocrinol (Lausanne). 2019;10:59. doi: 10.3389/fendo.2019.00059
16. 16. Khan, S. R., Chaker, L., Ruiter, R., Aerts, J. G., Hofman, A., Dehghan, A., Franco, O. H., Stricker, B. H., & Peeters, R. P. (2016). Thyroid Function and Cancer Risk: The Rotterdam Study. The Journal of clinical endocrinology and metabolism, 2019;101(12), 5030–6.doi:10.3389/fendo.2019.00059
17. 17. Søgaard M, Farkas DK, Ehrenstein V, Jørgensen JO, Dekkers OM, Sørensen HT. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. Eur J Endocrinol. 2016;174(4):409-14. doi: 10.1530/EJE-15-0989
18. 18. Fang Y, Yao L, Sun J, Yang R, Chen Y, Tian J, Yang K, Tian L. Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis. J Endocrinol Invest. 2017;40(10):1035-47. doi: 10.1007/s40618-017-0679-x
19. 19. Chan YX, Knuiman MW, Divitini ML, Brown SJ, Walsh J, Yeap BB. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer. Eur J Endocrinol. 2017;177(4):297-308. doi: 10.1530/EJE-17-0197
20. 20. Mondul AM, Weinstein SJ, Bosworth T, Remaley AT, Virtamo J, Albanes D. Circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer. PLoS One. 2012;7(10):e47730. doi: 10.1371/journal.pone.0047730
21. 21. Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender JB, Mayor P, Etter JL, Cramer DW, Diergaarde B, Doherty JA, Dörk T, Edwards R, deFazio A, Friel G, Goodman MT, Hillemanns P, Høgdall E, Jensen A, Jordan SJ, Karlan BY, Kjær SK, Klapdor R, Matsuo K, Mizuno M, Nagle CM, Odunsi K, Paddock L, Rossing MA, Schildkraut JM, Schmalfeldt B, Segal BH, Starbuck K, Terry KL, Webb PM, Zsiros E, Ness RB, Modugno F, Bandera EV, Chang-Claude J, Moysich KB. History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. Br J Cancer. 2017;117(7):1063-9. doi: 10.1038/ bjc.2017.267
22. 22. Hercbergs AH, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):432-6. doi: 10.1097/MED.0b013e32833d9710
23. 23. Patil VM, Noronha V, Joshi A, Bhattacharjee A, Goel A, Talreja V, Chandrasekharan A, Pande N, Mandal T, Ramaswamy A, Prabhash K. Influence of Hypothyroidism After Chemoradiation on Outcomes in Head and Neck Cancer. Clin Oncol (R Coll Radiol). 2018;30(10):675. doi: 10.1016/j.clon.2018.07.002
24. 24. Smith GL, Smith BD, Garden AS, Rosenthal DI, Sherman SI, Morrison WH, Schwartz DL, Weber RS, Buchholz TA. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck. 2009;31(8):1031-8. doi: 10.1002/hed.21066
25. 25. Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132(10):1041-6. doi: 10.1001/archotol. 132.10.1041
26. 26. Cella L, Conson M, Caterino M, De Rosa N, Liuzzi R, Picardi M, Grimaldi F, Solla R, Farella A, Salvatore M, Pacelli R. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1802-8. doi: 10.1016/j.ijrobp.2010.09.054
27. 27. Hancock SL, McDougall IR, Constine LS. Thyroid abnormalities after therapeutic external radiation. Int J Radiat Oncol Biol Phys. 1995;31(5):1165-70. doi: 10.1016/0360-3016(95)00019- U
28. 28. Yoden E, Soejima T, Maruta T, Demizu Y, Nishimura H, Ejima Y, Sasaki R, Yamada K, Sugimura K. (Hypothyroidism after radiotherapy to the neck). Nihon Igaku Hoshasen Gakkai Zasshi. 2004;64(3):146-50. Japanese
29. 29. Thomas O, Mahé M, Campion L, Bourdin S, Milpied N, Brunet G, Lisbona A, Le Mevel A, Moreau P, Harousseau J, Cuillière J. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys. 2001;49(1):125-31. doi: 10.1016/ s0360-3016(00)01373-0
30. 30. Nagayama Y, Kaminoda K, Mizutori Y, Saitoh O, Abiru N. Exacerbation of autoimmune thyroiditis by a single low dose of wholebody irradiation in non-obese diabetic-H2h4 mice. Int J Radiat Biol. 2008;84(9):761-9. doi: 10.1080/09553000802345910
31. 31. El-Shebiney M, El-Mashad N, El-Mashad W, El-Ebiary AA, Kotkat AE. Radiotherapeutic factors affecting the incidence of developing hypothyroidism after radiotherapy for head and neck squamous cell cancer. J Egypt Natl Canc Inst. 2018;30(1):33- 38. doi: 10.1016/j.jnci.2018.01.004
32. 32. Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, Murphy PB, Shyr Y, Cmelak AJ. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-andneck cancer. Int J Radiat Oncol Biol Phys. 2010;77(2):468-76. doi: 10.1016/j.ijrobp.2009.05.018
33. 33. Lo Galbo AM, Kuik DJ, Lips P, von Blomberg BME, Bloemena E, Leemans CR, deBree R. A prospective longitudinal study on endocrine dysfunction following treatment of laryngeal or hypopharyngeal carcinoma. Oral Oncol. 2013;49(9):950-955. doi: 10.1016/j.oraloncology.2013.03.450